NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of its novel cannabidiol-like therapeutic compounds to treat neurodegenerative and oxidative stress-related diseases. The publication titled, “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability” has been published in American Chemical Society’s ACS Medicinal Chemistry Letters.
Dean Petkanas, Chief Executive Officer of Kannalife stated, “My greatest appreciation goes out to all the scientists and professionals credited and cited for the body of science behind the publication of KLS-13019, for their steadfast efforts and deep rooted belief in the work we are performing at Kannalife. I also want to thank the American Chemical Society for acceptance of this publication and the peer review scientists who took the time to give their feedback and analysis of the science behind KLS-13019.”
The abstract, as well as the purchase of the full version of the publication on the Discovery of KLS-13019 is available on-line at: http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00009
About American Chemical Society – ACS Publications
The American Chemical Society (“ACS”) is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. The ACS was founded in 1876 and committed to sharing its professional work with a public audience. It began publishing its flagship journal, the Journal of the American Chemical Society (JACS), in April 1879. The ACS has over 160,000 members, more than 83 million ACS Journal article downloads, and published more than 42 million chemical abstracts. For more information, visit: www.acs.org - “Improving People’s Lives Through the Transforming Power of Chemistry.”
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com
Source:Kannalife Sciences, Inc.